Table 2.
MASCC–ESMO emetic risk groups 2023
| Intravenous agentsa | Emetic risk | Oral agentsb | Emetic risk |
|---|---|---|---|
| High | Risk in nearly all patients (>90%) | High/moderate | Risk in 30% or more of patients |
| Moderate | Risk in 30%-90% of patients | ||
| Low | Risk in 10%-30% of patients | Low/minimal | Risk in fewer than 30% of patients |
| Minimal | Fewer than 10% at risk |
ESMO, European Society for Medical Oncology; MASCC, Multinational Association of Supportive Care in Cancer.
a
Proportion of patients experiencing emesis in the first 24 h after start of intravenous antineoplastic agents in the absence of effective antiemetic prophylaxis. Nausea is not part of the risk classification.
b
The emetic potential of the oral anticancer agents is based on a full course of therapy and not a single dose within the first cycle.